ProMIS Neurosciences Unveils Phase 1b Trial for Alzheimer's Candidate PMN310

ProMIS Neurosciences Inc., a biotechnology company at the clinical stage aimed at creating precise therapies for neurodegenerative diseases, announced the start of its phase 1b trial (PRECISE-AD) assessing its primary therapeutic candidate, PMN310, for Alzheimer’s disease (AD).PMN310, a humanized IgG1 antibody, is designed to selectively bind to toxic oligomers of amyloid-beta (AßO)—thought to be a major contributor to Alzheimer’s disease pathology—while steering clear of plaque deposits. 

This system is intended to minimize the likelihood of amyloid-related imaging abnormalities (ARIA), a frequent adverse effect linked to current treatments, which may provide a unique product profile. The current phase 1b PRECISE-AD trial will evaluate the safety, tolerability, and pharmacokinetics of PMN310 during 12 months of treatment in 100 patients suffering from mild cognitive impairment (MCI) caused by AD (Stage 3 AD) or early AD (Stage 4 AD). 

The research will additionally assess important biomarkers and clinical efficacy measures to collect information on the therapeutic potential of PMN310. Findings from the recently finalized phase 1a clinical trial involving healthy participants indicated a predominantly positive safety and tolerability profile, with drug levels in cerebrospinal fluid backing its potential for strong target interaction in individuals with AD.

“The initiation of the PRECISE-AD trial is a major milestone in our journey to develop PMN310 as a potential treatment for AD,” said Neil Warma, CEO of ProMIS Neurosciences. “Current AD treatments offer only modest efficacy, often accompanied by significant side effect challenges such as ARIA, leaving a substantial unmet need for new options. We believe PMN310 has the potential to deliver on this need through its selective targeting mechanism.”